ADAM17 is an inducible metalloprotease that cleaves membrane-anchored proteins involved in a variety of homeostatic and pathophysiological processes. The mechanisms responsible for activation and gene expression of ADAM17 are a matter of debate, as they depend on the cellular context. Here we investigate the role of the tetraspanin, CD9, in regulating the shedding activity and gene expression of ADAM17 in human aortic endothelial cells. In contrast to what has been previously reported for other substrates of ADAM17, we found that a deficiency of CD9 did not increase ADAM17-dependent shedding of CX3CL1. Instead, knockdown of CD9 resulted in a reduction in immature and mature ADAM17 protein. This reduction was not caused by an increase in ADAM17 degradation, but rather a decrease in ADAM17 transcription. We found an associated reduction in constitutive and TNF-α-induced NF-κB activation upon knockdown of CD9, which may potentially explain the reduction in its downstream target, ADAM17.